News for Ocular Therapeutix, Inc. (OCUL)

FMR LLC (Trades, Portfolio)'s Recent Transaction with Ocular Therapeutix On June 30, 2025, FMR LLC (Trades, Portfolio) made a significant move by acquiring 18,6

Summary Ocular Therapeutix Inc (OCUL), a biopharmaceutical company dedicated to improving retinal disease treatment, announced the launch of its new corporate b

U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Tuesday. Shares of Carnival Corporation CCL rose sharply during Tuesday's sessio...

Ocular Therapeutix (OCUL) to present key findings at Clinical Trials at the Summit 2025 in Las Vegas. Presentations include Phase 1 results for wet AMD

Summary Ocular Therapeutix Inc (OCUL), a biopharmaceutical company focused on transforming the retina experience, announced its participation in the Clinical Tr

Ocular Therapeutix (OCUL) has received continued support from HC Wainwright & Co. as analyst Yi Chen reiterates the

Ocular Therapeutix (OCUL) stock rises as its Phase 3 trial for lead asset Axpaxli in wet AMD nears enrollment target. Read more here.

**media[638993]**

**media[625358]**

On May 6, 2025, Ocular Therapeutix (OCUL) was the subject of an updated analyst rating from Needham. Notably, analyst Serge Belanger maintained a "Buy" rating f

Ocular Therapeutix Inc (OCUL) demonstrates a robust proprietary hydrogel platform technology, positioning it as a leader in ophthalmic therapies.Despite a stro

Summary Ocular Therapeutix Inc (OCUL), a biopharmaceutical company focused on retinal diseases, announced its financial results for the first quarter ending Mar

As of March 31, 2025, Ocular Therapeutix (OCUL) reported $349.7 million in cash and cash equivalents. The company anticipates that these funds, coupled with exp

\nRevenue: $10.7 million, falling short of the estimated $16.83 million, marking a 27.6% decrease year-over-year.Earnings Per Share (EPS): Reported at $(0.38), m

\n Ocular Therapeutix (OCUL) reports Q1 2025 revenue of $10.7 million, a 27.6% decline year-over-year. Net loss for Q1 2025 was $64.1 million or $0.38 per

**media[608641]**

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

On March 21, 2025, Opaleye Management Inc. (Trades, Portfolio) executed a significant transaction by acquiring an additional 350,000 shares of Codexis Inc. This

On March 18, 2025, Opaleye Management Inc. (Trades, Portfolio) executed a strategic transaction involving Harrow Inc., a U.S.-based eyecare pharmaceutical compa